Improving Quality of Life of Prostate Cancer Survivors With Androgen Deficiency

Inclusion Criteria:

Men with prostate cancer, who have Stage pT2, N0, M0 lesions (confined to the gland); Combined Gleason score of 7 (3+4 elements) or less; Preoperative PSA less than 10 ng/ml; Stable and undetectable PSA level (PSA less than 0.1 ng/mL using an assay that has a functional sensitivity of 0.1 ng/mL) for at least two years after radical prostatectomy.

Age: 40 years and older
Presence of symptoms related to sexual dysfunction, fatigue/low vitality, or physical dysfunction.
An average of two fasting, early morning serum testosterone levels, measured by LC-MS/MS, less than 275 mg/dL and/or free testosterone by equilibrium dialysis <60 pg/mL. middle-aged and older men with mean testosterone levels > 300 ng/dL.
Ability and willingness to provide informed consent

Exclusion Criteria:

Men who have undergone radiation therapy
Men receiving androgen deprivation therapy will be excluded.
Hemoglobin <10 g/dL or >16.5 g/dL
Severe untreated sleep apnea
Allergy to sesame oil
Uncontrolled heart failure
Myocardial infarction, acute coronary syndrome, revascularization surgery, or stroke within 3 months
Serum creatinine >2.5 mg/dL; ALT 3x upper limit of normal;
Hemoglobin A1c >7.5% or diabetes requiring insulin therapy
Body mass index (BMI) >40 kg/m2
Untreated depression. Subjects with depression who have been on stable anti-depressant medication, or undergoing CBT for more than three months are eligible.
Men with axis I psychiatric disorder, such as schizophrenia, will be excluded.
Subjects who have used the following medications within the past 6 months: testosterone, DHEA, estrogens, GnRH analogs, antiandrogens, spironolactone, ketoconazole, rhGH, megestrol acetate, prednisone 20 mg daily or equivalent doses of other glucocorticoids for more than two weeks